The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001237370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
11/09/2026
Date registered
Help: Date registered
13/10/2026
Date last updated
Help: Date last updated
11/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
13/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Can functional tomography angiography (FTA) detect subtle changes to blood flow regulation due to nicotinamide (vitamin B3) in people with glaucoma?
Scientific title
Retinal Flow Response to Nicotinamide via Functional Tomography Angiography (NiFTy): A 12-week, single-centre, open-label, randomised crossover trial of nicotinamide supplementation in glaucoma assessed by functional tomography angiography
Additional trial identifiers [1] 316986 0
Nil
Universal Trial Number (UTN)
U1111-1338-7853
Trial acronym
NiFTy
Related trial records

Health condition
Health condition(s) studied:
Glaucoma 341444 0
Condition category
Condition code
Eye 337508 337508 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Two interventions will be used, a drug (open label) and a medical device.
Drug: nicotinamide
Form and mode of delivery: 1000mg oral tablet
Dosage instructions (all tablets to be taken with food and water):
Week 1: one tablet (1000mg) a day,
Week 2: two tablets (1000mg each) a day (one in the morning, one in the evening),
Week 3 - Week 6: three tablets (1000mg each) a day (one in the morning, two in the evening).
Study visits: There will be 3 study visits in total, occurring every 6 weeks.
Visit 1 occurs at time of enrolment, before randomisation and commencement of nicotinamide dosing.
Visit 2 occurs 6 weeks after randomisation, and Visit 3 occurs 12 weeks after randomisation.
As it is a crossover trial, participants will be randomised to receive nicotinamide tablets EITHER at Visit 1 (Arm A), or at Visit 2 (Arm B).
All participants will be seen after taking nicotinamide for 6 weeks, at either Visit 2 (Arm A) or Visit 3 (Arm B).

Adherence: email reminders will be used, and the tablets will be counted at the next study visit.
Mode of delivery: intervention drug taken orally by participants at home.
Washout: no official washout period is required. Nicotinamide has a half life of 7-9 hours, and we have previously shown that it no longer has an effect on the eye 6-weeks after stopping the intervention, even at high doses like what will be used in this trial. All study participants will be seen at 6-week intervals to ensure that no washout period is required.

Device:
Form: a non-invasive device with a range of 8 LEDs that fits around the lens of an optical coherence tomography (OCT) camera. The OCT camera is a conventionally used clinical device that can non-invasively image the blood vessels and tissue at the back of the eye.
The intervention device is used to deliver a flickering light to the eye at 10 Hz whilst simultaneously imaging with the camera. This imaging process is called "functional tomography angiography" (FTA).
Light exposure: <1 min at a time for each image scan, 4 images acquired per eye.
Total exposure to flickering light: < 5 minutes per eye
Control of device: device powered by USB to the computer
FTA imaging of the eye will be conducted at every study visit (three visits in total, 6 weeks apart).
Intervention code [1] 333729 0
Early detection / Screening
Intervention code [2] 335125 0
Diagnosis / Prognosis
Description of the comparator or control
Control: people diagnosed and treated with glaucoma, undergoing standard of care treatment. "Standard care" means that people are receiving/have received treatment to manage their glaucoma, either with eyedrops, laser therapy or glaucoma surgery.

The trial is a crossover design, so all participants enrolled in the trial will be given nicotinamide + standard care for 6 weeks, or standard care alone for 6 weeks, in randomised order. All participants will undergo eye imaging with FTA at every study visit. All FTA imaging will be conducted at CERA in-person by the research team.

There will be 3 study visits in total, occurring every 6 weeks.
Visit 1 occurs at time of enrolment, before randomisation and commencement of nicotinamide dosing.
Visit 2 occurs 6 weeks after randomisation, and Visit 3 occurs 12 weeks after randomisation. As it is a crossover trial, participants will be randomised at the end of Visit 1 to receive nicotinamide tablets EITHER at Visit 1 (Arm A), or at Visit 2 (Arm B).

Participants randomised to Arm B will continue their standard of care treatment for 6 weeks. They will be seen at Visit 2 (6-weeks after Visit 1), after which they will receive nicotinamide tablets.
Control group
Active

Outcomes
Primary outcome [1] 346605 0
Changes to Functional Tomography Angiography (FTA) metrics following nicotinamide use in people with glaucoma
Timepoint [1] 346605 0
The primary time point is the end of the six-week nicotinamide treatment period. We will be investigating the change in FTA signal from pre-treatment to end of treatment (i.e., baseline [Visit 1] vs Week 6 [Visit 2] for Arm A where nicotinamide is prescribed first; or Visit 2 vs Visit 3 [Week 12] for Arm B where standard care is prescribed first). The analysis metric will be within-participant change from start to end of each treatment period.
Secondary outcome [1] 466676 0
Changes to OCTA imaging after 6-weeks of nicotinamide treatment compared to standard care
Timepoint [1] 466676 0
- Baseline - 6 weeks post-baseline (6 weeks post-1st treatment (intervention or control)) - 12 weeks post-baseline (6 weeks post-2nd treatment (intervention or control))
Secondary outcome [2] 466678 0
Changes to OCT imaging after nicotinamide treatment compared to standard care
Timepoint [2] 466678 0
- Baseline - 6 weeks post-baseline (6 weeks post-1st treatment (intervention or control)) - 12 weeks post-baseline (6 weeks post-2nd treatment (intervention or control))
Secondary outcome [3] 466679 0
Changes to perimetry indices following nicotinamide treatment compared to standard care
Timepoint [3] 466679 0
- Baseline - 6 weeks post-baseline (6 weeks post-1st treatment (intervention or control)) - 12 weeks post-baseline (6 weeks post-2nd treatment (intervention or control))
Secondary outcome [4] 466682 0
Changes to contrast sensitivity post nicotinamide treatment compared to standard care
Timepoint [4] 466682 0
- Baseline - 6 weeks post-baseline (6 weeks post-1st treatment (intervention or control)) - 12 weeks post-baseline (6 weeks post-2nd treatment (intervention or control))
Secondary outcome [5] 468355 0
Changes to perimetry indices following nicotinamide treatment compared to standard care
Timepoint [5] 468355 0
- Baseline - 6 weeks post-baseline (6 weeks post-1st treatment (intervention or control)) - 12 weeks post-baseline (6 weeks post-2nd treatment (intervention or control))

Eligibility
Key inclusion criteria
• Aged 18 years or older at the time of consent
• Confirmed diagnosis of primary open-angle glaucoma, normal-tension glaucoma, or pseudoexfoliative glaucoma, established by a qualified ophthalmologist
• On stable glaucoma therapy for 3 months or more prior to enrolment
• Reproducible visual field defect (MD between -2dB and -12dB) on standard automated perimetry (Humphrey Field Analyser; at least two consistent tests within 6 months), Glaucoma Hemifield Test (GHT) is Outside Normal Limits.
• Confirmed retinal nerve fibre layer (RNFL) loss on OCT imaging
• Refractive error < -6D myopia and < -2DC astigmatism (or history of high myopia if participant has had cataract surgery)
• Able to provide written informed consent in English
• Able and willing to attend all three scheduled study visits
• Able and willing to abstain from nicotinamide-containing supplements and multi-B vitamins for the duration of the trial (and for 2 weeks prior to the baseline visit if currently taking these supplements)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• History of photosensitive epilepsy or a family history of photosensitive epilepsy (first-degree relative)
• Known hypersensitivity or allergy to nicotinamide or any ingredient in the study supplement formulation
• Known chronic liver or kidney disease
• Current use of nicotinamide supplementation or any multi-B vitamin supplement that cannot be discontinued for the trial duration
• Significant anterior or posterior segment media opacity (e.g., cataract, vitreous haemorrhage) likely to preclude adequate OCTA image quality, as determined by the research team
• Secondary glaucoma not attributable to primary open-angle mechanisms (e.g., neovascular, uveitic, or traumatic glaucoma)
• Current participation in another interventional clinical trial involving a medicinal product or device
• Diagnosis of any systemic condition for which nicotinamide is contraindicated (e.g., active peptic ulcer disease, hepatic impairment)
• Diagnosis of any systemic or ocular condition that may affect retinal blood vessels (e.g., diabetic retinopathy, uncontrolled hypertension)
• Pregnancy, breastfeeding, or intention to become pregnant during the trial period
• Inability to comply with study procedures or follow-up requirements, as assessed by the investigator

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computer generated, permuted block randomisation
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321581 0
Charities/Societies/Foundations
Name [1] 321581 0
CASS Foundation
Country [1] 321581 0
Australia
Primary sponsor type
Other
Name
Centre for Eye Research Australia
Address
Country
Australia
Secondary sponsor category [1] 325928 0
None
Name [1] 325928 0
Address [1] 325928 0
Country [1] 325928 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320110 0
St Vincent's Hospital Melbourne Human Research Ethics Committee
Ethics committee address [1] 320110 0
Ethics committee country [1] 320110 0
Australia
Date submitted for ethics approval [1] 320110 0
17/08/2026
Approval date [1] 320110 0
15/10/2026
Ethics approval number [1] 320110 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149466 0
Dr Flora Hui
Address 149466 0
CERA, Level 10, 200 Victoria Parade, East Melbourne, Victoria 3002
Country 149466 0
Australia
Phone 149466 0
+61 3 9959 0068
Fax 149466 0
Email 149466 0
Contact person for public queries
Name 149467 0
Flora Hui
Address 149467 0
CERA, Level 10, 200 Victoria Parade, East Melbourne, Victoria 3002
Country 149467 0
Australia
Phone 149467 0
+61 3 9959 0068
Fax 149467 0
Email 149467 0
Contact person for scientific queries
Name 149468 0
Flora Hui
Address 149468 0
CERA, Level 10, 200 Victoria Parade, East Melbourne, Victoria 3002
Country 149468 0
Australia
Phone 149468 0
+61 3 9959 0068
Fax 149468 0
Email 149468 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
• Published results
• Primary outcome(s)
• Safety data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Data repository: Data may be uploaded to ARDC in the future. Prior to this, the Principal Investigator of the trial can be contacted for access ([email protected])

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.